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ABSTRACT 
 
Metastasis is responsible for the majority of cancer related deaths. In breast cancer the 
lungs and bones are the major sites for metastasis. Previous studies used the metastatic 
aggressive MDA-MB-231 breast cancer line to isolate subclones that preferentially 
invade the lungs (LM line) or bones (BoM line). While genes associated with the tissue 
specific metastasis have been identified, it is unknown if metabolic adaptations contribute 
to the growth of the LM and BoM lines in their respective organs. The goal of this study 
was to test the hypothesis that the LM and BoM lines exhibit differences in glucose and 
glutamine metabolism from their parent MDA-MB-231 breast cancer line. Such 
differences would support the broader concept of metabolic plasticity as an important 
component of cancer metastasis. We used 13C- metabolic flux analysis with 5-13C 
glutamine as the labeled substrate. The rates of glucose uptake, glutamine uptake, 
respiration, and lactate production were measured, together with 13C enrichment of 
lactate. In parallel, the fraction of glutamine and glucose used for fatty acid synthesis was 
assessed with the fatty acid synthase inhibitor C75. The measured fluxes were used to 
determine fluxes through glycolysis, the pentose phosphate pathway, the tricarboxylic 
acid (TCA) cycle, malic enzyme, and to fatty acids. The LM and BoM cells exhibited 
significant metabolic differences from each other and the MDA231 parent line, this 
supports our hypothesis and is consistent with such changes contributing to organ-
specific growth of these lines. Specifically, the LM and BoM lines have significantly 
lower mitochondrial TCA cycle and respiratory chain activities. The LM cells have a 
significantly higher malic enzyme flux, which together with restricted mitochondrial 
activity, are proposed to reduce oxidative stress in the high oxygen environment of the 
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lungs. The BoM cells that metastasize to bones consume significantly less glutamine and 
have low mitochondrial activity suggesting they rely more heavily on aerobic glycolysis 
for ATP synthesis in the oxygen-limited bone environment. These metabolic adaptations 
suggest that organ specific metabolic difference may be a new way to potentially target 
these cells through development of drugs. 
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INTRODUCTION 
 
A hallmark of cancer cells is their altered metabolism that was first demonstrated 
as enhanced glycolytic production of lactate by Otto Warburg. Even when sufficient 
oxygen is available to fully oxidize glycolytic-derived pyruvate in mitochondria, a greater 
proportion of pyruvate is instead reduced to lactate; this phenomenon is known as the 
Warburg effect, or aerobic glycolysis (6). It is thought to have a role in supporting rapid 
cell proliferation by provision of ATP and/or glycolytic intermediates at a rate sufficient 
to meet the biosynthetic demands (12). The metabolic demands placed on the anabolic 
reactions partly depend on the types of concentrations of nutrients that can be imported 
from the environment (11). For example, cancer cells have high demand for fatty acids to 
synthesize phospholipids for new membranes. If exogenous fatty acids are limiting, 
tumors must have the capacity to use glucose and/or glutamine for de novo synthesis. The 
latter substrate is typically imported at a rate more than ten-fold greater than that of 
untransformed cells and can be used to re-supply TCA cycle intermediates, and for the 
synthesis of glutathione, ATP, NADPH and other metabolites important for proliferation 
(6).   
 While metastatic cancers often exhibit higher rates of aerobic glycolysis than non-
malignant ones, it is unclear if the Warburg effect, or other characteristics of their 
metabolic phenotype, varies as one or a few cells preferentially invade and grow in 
different secondary tissues (10). Each secondary site represents a potentially distinct 
microenvironment that may necessitate subtle adjustments in the tumor’s metabolic 
phenotype for success (7). Besides distinct tissue microenvironments, metastasis to one 
or more secondary sites depends on genetic heterogeneity within the primary tumor. 
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Transcriptomics studies have been performed on the MDA-MB-231 breast cancer line 
that commonly metastasizes to the bones and lungs (7). Highly selective bone or lung 
metastasizing subclones (denoted BoM and LM lines, respectively) were developed from 
injections of MDA-MB-231 cells into mice; lung and bone tumors were iteratively 
isolated, expanded in culture then re-introduced in mice until the resulting lines 
exclusively invaded either the lungs or bone when injected into immune deficient mice 
(7, 8).  The bone metastatic cells were not able to grow in the lungs demonstrating that 
metastatic cells that grow well in one location may not grow well at another (8).  In the 
bone cell lines overexpression of interleukin-11(IL-11) and osteoponitin (OPN) with the 
addition of chemokine receptor 4 (CXCR4) increases bone metastasis activity (10). In the 
MDA-MB-231 cell line 10% of the cells contained CXCR4 which was in the bone 
metastasis gene expression. When looking at the gene set for lung expression there was 
only six genes the overlapped with the bone metastasis gene expression (7).  
Overexpression of SPARC and ID1 significantly associated with metastasis to lung (10). 
When examining the primary breast cancer tumors those expressing the lung metastasis 
signature had higher activity while the bone metastasis signature did not (7). There are no 
genes found that are overexpressed in LM or BoM that participate in metabolic pathways. 
However, this does not eliminate the possibility of metabolic differences between these 
cell lines. 
 We hypothesized that tissue-specific metastasis is associated with subtle 
differences in metabolic reprogramming of glucose and glutamine metabolism to allow 
continued proliferation and invasion in different organ microenvironments. Metabolic 
differences in the cell lines could be because the microenvironment of the new organ to 
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which they invade is different from where the tumor originally grew. Therefore, the aim 
of the study was to determine whether the LM and BoM subclones have metabolic 
variations relative to the original breast cancer line from which they are derived. In order 
to test this hypothesis, we used a combination of pharmacological inhibitor studies and 
13C lactate labeling experiments with 5-13C glutamine.  
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METHODS 
A. Cell lines and culture 
Metastatic breast cancer MDA-MB-231 cells (hereafter referred to as MDA231) 
and the less aggressive T47D breast cancer cells were provided by Dr. Y.D. Zhou 
(University of Mississippi, Department of Chemistry and Biochemistry). Sub-clones of 
MDA231 cells that preferentially metastasize in lung (LM) and bone (BoM) were 
generated by Massague’s lab (7,14). Both LM and BoM cells were obtained from Dr. 
Kounosuke Watabe (Wake Forest University) and provided by Dr. Zhou. Cells were 
routinely cultured using RPMI-1640 media supplemented with 10% fetal bovine serum 
and 0.5% vol/vol penicillin-streptomycin in 10 cm polystyrene petri dishes at 37oC in a 
humidified 5% CO2 incubator. Cells were maintained in culture for no more than 20 
passages, and typically split twice a week. The day before each experiment, 
approximately 1.0 x 106 cells were seeded in each well of 2-well Lab-Tek chambers. 
Control wells received 2mL standard cell culture media while treatment wells were 
incubated in glutamine-free RPMI-1640 media supplemented with 1.5 mM 5-13C 
glutamine. Cells were incubated for 20-22 hours prior to experiments. 
B. Materials (reagents) 
Glutamate pyruvate transaminase, glucose-6-phosphate dehydrogenase (G6PDH), 
lactate dehydrogenase, nicotinamide adenine dinucleotide phosphate (NADP), 
nicotinamide adenine dinucleotide (NAD), adenosine triphosphate (ATP), and 2 
oxoglutarate were purchased from Calzyme (San Luis Obispo, CA). Hexokinase, 
microbial glutamate dehydrogenase, 3-nitrophenylhydrazine, and N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide (EDC) were purchased from Sigma (St. 
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Louis, MO). Glutaminase was purchased from Megazyme (Chicago, IL). 5-13C glutamine 
was purchased from Cambridge Isotopes (Tewksbury, MA). Cell culture media, fetal 
bovine serum, and cell culture supplies were purchased from Fisher Scientific (Pittsburg, 
PA). Buffers and other general reagents were purchased from Sigma. 
C. Flux experiments 
After overnight incubation in cell culture media  5-13C glutamine, cells were 
rinsed then equilibrated 5 h 37oC in experimental buffer containing 137 mM NaCl, 5 mM 
KCl, 20 mM TES, 1.3 mM CaCl2, 1.3 mM MgCl2, 1.2 mM Na2SO4, 0.4 mM KH2PO4, 
0.2 mM NaHCO3, 5.5 mM glucose, 0.3 % fatty acid-free bovine serum albumin (BSA),  
1.5 mM 5-13C glutamine, pH 7.4. For some experiments, 40 M C75 (an inhibitor of fatty 
acid synthase) was included in buffer containing 1.5 mM unlabeled glutamine to estimate 
the proportion of glucose and glutamine used for fatty acid synthesis. The control buffer 
contained no glutamine.  Respiration rate of cells in each well was determined at 37oC in 
2.15 mL fresh buffer using a custom-made setup with a Clark-type micro-oxygen 
electrode (Micrelectrodes, Inc., Bedford MA) (Fig. 2). Data for each well was acquired 
over 45-55 min. with a Powerlab A/D unit and Lab Chart software (AD Instruments). 
Cells were rinsed once with buffer then serially incubated for 60 min, 120 min, and 60 
min at 37oC with 350 L buffer. After each incubation period, buffer was collected in 
microfuge tubes on ice, the cells were rinsed once, and then 350 L buffer added for the 
next incubation period. Control wells without cells were incubated in parallel to correct 
for evaporative volume changes over each incubation period. The samples were 
centrifuged for 5 min. 4oC at 21,000 xg and supernatants stored at -20oC for metabolite 
assays and mass spectrometry. The 60 min. incubations were used to assess average rates 
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of glucose consumption and lactate production, while all three were used to assess 
glutamine consumption. Cell pellets were visible for the MDA231 samples; these were 
saved and assayed for protein content to correct for protein loss over each incubation 
period. After the final incubation, wells were rinsed once with 1 ml phosphate buffered 
saline (PBS) then solubilized for 15min at 37oC with 500 L 50 mM NaCl, 20 mM TES, 
1% SDS, pH 7.3. The extracts were vortexed 2-3 min. then centrifuged 10 min. 21,000xg 
10oC and the supernatants stored at -20oC for protein assay. The MDA231 cell pellets 
were washed once with 200 L PBS, repelleted by centrifugation, then solubilized with 
100 L SDS buffer and stored at -20oC. 
 
 
 
Figure 1: This figure shows the set up for respiration measurement.  Shown are the cells plated at the 
bottom of chamber. A stir bar located in the media is being turned by a magnetic stirrer on the other side 
of the cell chamber lid. In the container is an O2 electrode which measures the decreasing oxygen 
concentration of the buffer.  
 
D. Metabolite assays 
D.1. Glucose Assay 
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The samples and standards (5 l; run in triplicate) were added to 115 l buffer 
containing 100 mM triethanolamine, 7 mM MgCl2, 2 mM ATP, 2 mM NADP, 1 U/ml 
hexokinase, and 1 U/ml glucose-6-phosphate dehydrogenase, pH 7.3. Reduction of 
NADP to NADPH occurs as glucose is oxidized over the 8-10 min incubation period. 
The resulting samples were measured in a Shimadzu RF6000 spectrofluorophotometer 
(ex = 341 nm, em = 464 nm). 
D.2. Glutamine Assay 
The samples and standards (6 l; run in duplicate) were added to 34 l buffer 
containing 60 mM sodium acetate pH 4.9 with or without 1 U/ml glutaminase. 
Glutaminase was used to convert glutamine to glutamate by cleaving the amino group to 
release free ammonia. The samples were incubated in a water bath (37C) for 45 minutes. 
After the incubation, the samples were added to another buffer which contained 300 mM 
TRIS, 10 mM 2-oxoglutarate, 240 µM NADPH, and 2 u/mL of glutamate dehydrogenase. 
The glutamate dehydrogenase catalyzed the reductive amination of 2-oxoglutarate to 
glutamate using the free ammonia generated by the glutaminase reaction. This was 
incubated for 1 hour and 30 minutes at room temperature in the dark because NADPH is 
light sensitive. The samples were then measured in a Shimadzu RF6000 
spectrofluorophotometer (ex = 341 nm and em = 464 nm).  Our cells naturally produce 
ammonia so to differentiate we run the standard without glutaminase and subtract the 
NADPH fluorescence’s. 
D.3. Lactate Assay 
The samples and standards (5 l; run in triplicate) were added to 115 l buffer 
containing 100 mM glycylglycine, 100 mM glutamate, 2 mM NAD, 1 U/ml lactate 
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dehydrogenase, and 1 U/ml glutamate-pyruvate transaminase, pH 8.5. In this reaction (40 
min), lactate is oxidized to pyruvate, NADH is produced, and pyruvate is removed by 
transamination to facilitate conversion o f lactate to pyruvate. The samples were 
measured in a Shimadzu RF6000 spectrofluorophotometer (ex = 341 nm, em = 464 
nm).  
D.4. Protein Assay 
Quantitation of total protein in soluble cell extracts (duplicates, diluted 1:3 in 
water) were determined by bicinchoninic acid (BCA) assay. Reactions (25 µl sample with 
500 µl BCA reagent) were incubated for 30 min, 60oC, cooled, and quantitated at 562nm 
using a Ultrospec 3100pro spectrophotometer (Amersham Biosciences). Bovine serum 
albumin standards (0, 50, 100, 150, 200, 300, 400, and 500 ug/ml) dissolved in 
solubilization buffer were run in parallel.  Additionally, protein assays were run for the 
MDA cell pellets to correct for protein lost over each incubation period. The MDA cells 
have a much lower adherence to the plate than the three other lines. Due to this inequality 
MDA cells were spun into pellets and assayed to measure the protein content as a form of 
compensation to account for the cell loss during the experiment.  
E. Lactate derivatization and mass spectrometry analysis of 13C lactate 
UHPLC–MS/MS of derivatized lactate 
The samples and lactate standards (14 l) were extracted with 2 volumes 100% 
cold methanol and then incubated for 1 H , -20C, to precipitate buffer proteins. The 
samples were then centrifuged at 21,000 xg, 2C for 10 min. The resulting supernatant was 
then transferred to new tubes. Next the reagents 50 mM EDC (prepared fresh in 1.5% 
pyridine, 98.5% ethanol, 21 l) and 140 mM NPH (prepared fresh in 50% ethanol, 21 l) 
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were added to the tubes in that specific order to derivatize lactate with 3- 
nitrophenylhydrazine. The reaction was incubated for 2 h, 37C, and then cooled on ice. 
The samples (30 l) were then diluted in 970 l 80% methanol in mass spec vials for 
analysis by liquid chromatography-triple quadrupole mass spectrometry.  Both unlabeled 
(M), 13C labeled (M1), and 66:1 M:M1 lactate standards were run to confirm the expected 
masses (224 Da for M, 225 Da for M1) and verify separation of these isotopologues.  
The derivatized samples were separated on a Waters ACQUITY I-Class UPLC™ system 
including binary solvent manager, sample manager and column manager connected to a 
Waters Xevo TQ-S triple quadrupole mass spectrometer (Waters Corp, Milford, MA, 
USA). The separation was carried out on a Waters Acquity UPLC™ BEH C18 column 
(50mm × 2.1mm i.d., 1.7 µm). The sample temperature and column temperature were 
maintained at 10 C and 40 C, respectively. The mobile phase consisted of water 
containing 0.1% formic acid (v/v) (A) and acetonitrile with 0.1% formic acid (B). The 
analysis was performed using the following gradient elution at a flow rate of 0.50 mL/min: 
0-2.5 min, 5% B to 18% B; 2.5-3 min, 18% B to 100% B. Each run was followed by a 2.5 
min wash with 100% B and an equilibration period of 2.5 min with the initial conditions. 
The strong and weak solutions used to wash the auto sampler were 
methanol/acetonitrile/isopropanol/water (25:25:25:25, v/v/v/v/v) and methanol/water 
(70:30, v/v), respectively. The injection volume was 1 μl. The UHPLC effluent was 
introduced into the Waters Xevo TQ-S mass spectrometer equipped with electrospray 
ionization in negative ion mode (ESI-) for quantification of the analytes. Detection was 
obtained by Multiple Reaction Monitoring (MRM) mode including two MRMs for 
confirmation of the analytes. MRM transitions and related parameters are listed in Table 1. 
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The quantification of analytes 224, 225, 226, and 227 (the expected masses for M, M1, 
M2, and M3 lactate derivatized with nitrophenylhydrazine, respectively) was acquired with 
transitions of deprotonated ion at m/z 224.04 → 152.06 for M, 225.04 → 152.06 for M1, 
226.04 → 152.06 for M2, and 227.04 → 152.06 for M3 with dwell time of 20 msec at cone 
voltage 44 V and collision energy 14 eV for each transition. The ESI–MS/MS parameters 
were set as follows: capillary voltage, 1.20 kV; cone voltage, 44 V; source temperature, 
150 C; desolvation temperature, 600 C; desolvation gas flow, 600 L/h, cone gas flow, 
200 L/h. Nitrogen was used as desolvation and cone gas. Argon (99.99% purity) was 
introduced as the collision gas into the collision cell at a flow rate of 0.15 mL/min. Data 
acquisition was carried out by MassLynx 4.1 software and processed by TargetLynx 
(Waters Corp., Milford, MA, USA). 
Table 1 Optimized UHPL-MS/MS parameters for each analyte 
Analyte 
[M-H]-  
(m/z) 
MRM transition  
(m/z) 
Cone 
votage (V) 
Collision 
energy (eV) 
Retention 
time (min) 
M 224.04 224.04 -> 152.06 
224.04 -> 137.11 
44 
 
14 
22 
1.84 
M1 225.04 225.04 -> 152.06 
225.04 -> 137.11 
44 
 
14 
22 
1.84 
M2 226.04 226.04 -> 152.06 
226.04 -> 137.11 
44 
 
14 
22 
1.84 
M3 227.04 227.04 -> 152.06 
227.04 -> 137.11 
44 
 
14 
22 
1.84 
 
F. Flux Calculations 
For 13C glutamine experiments, measured fluxes include glucose uptake (J0), 
lactate production (J4), mitochondrial respiration rate (JRR), and external glutamine 
consumption (J10)., For C75 experiments, the fraction of glucose or glutamine used for 
fatty acid synthesis 1 −
𝐽 𝐶75
𝐽 𝑐𝑛𝑡𝑙
 , and the fraction of C75-senstive glucose diverted to lactate 
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for ATP synthesis 
0.5(𝐽4𝑐𝑛𝑡𝑙− 𝐽4𝐶75)
𝐽0𝑐𝑛𝑡𝑙− 𝐽0𝐶75
 were measured. These data, along with 13C enrichment 
in lactate, were the basis for assessing all intracellular fluxes using a Microsoft Excel-
based computational model to optimize the following parameters: malic enzyme (J7) 
contribution to total pyruvate produced, 
𝐽7
𝐽2𝑐+𝐽7
= 𝑋 (where J2c = glycolytic flux from 3-
phosphoglycerate to pyruvate) , glutamate dehydrogenase (J11) contribution to total 
alpha-ketoglutarate produced, 
𝐽11
𝐽11+𝐽12𝑓
= 𝑌, and the fraction of exogenous glutamine 
oxidized to -ketoglutarate, 
𝐽11
𝐽10
= 𝑍. The 14 fluxes not measured can be calculated from 
the measured fluxes and model-optimized parameters as detailed below, provided that the 
cells maintain a metabolic steady-state (i.e., the production and consumption of each 
metabolite is equal). Mitochondrial respiration rate was not directly used to calculate 
fluxes, but was important in providing constraints for calculation of fluxes through the 
TCA cycle reactions. 
Given that the model finds the solution 
𝐽11
𝐽10
= 𝑍 it follows that the rate of 
glutamate oxidation to KG is calculated as: 
𝐽11 = 𝐽10 ∙ 𝑍                                                                          (Eq.1) 
The reductive carboxylation of KG to citrate (J12r) for fatty acid synthesis is calculated 
from the C75-sensitive glutamine consumption: 
  𝐽12𝑟 = 𝐽10 ∗ (1 −
𝐽10𝐶75
𝐽10𝑐𝑛𝑡𝑙
)                                                           (Eq. 2) 
Given the solution 
𝐽11
𝐽11+𝐽12𝑓
= 𝑌, the forward oxidation of citrate to KG is calculated by 
solving for J12f: 
 𝐽12𝑓 =
𝐽11(1−𝑌)
𝑌
                                                                (Eq.3) 
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The glucose consumption for fatty acid synthesis was calculated by subtracting the C75-
sensitive glucose converted to lactate from the total C75-sensitive glucose uptake: 
  𝑔𝑙𝑐 𝑓𝑜𝑟 𝐹𝐴 = 0.36 ∗ [𝐽0 ∗ (1 −
𝐽0𝐶75
𝐽0𝑐𝑛𝑡𝑙
) − 0.5 ∗ 𝐽0 ∗ (
𝐽4𝑐𝑛𝑡𝑙−𝐽4𝐶75
𝐽0𝑐𝑛𝑡𝑙−𝐽0𝐶75
)]                   (Eq. 4) 
Equation 4 assumes that 11 glucose are required to synthesize each palmitate; four (36%) 
are used as the carbons for the fatty acid and seven (64%) are used by the oxidative PPP 
to generate the 14 NADPH required for palmitate synthesis. The rate of citrate used for 
fatty acid synthesis is thus: 
 𝐽13 = 𝐽12𝑟 + 2 ∗ (𝑔𝑙𝑐 𝑓𝑜𝑟 𝐹𝐴)                                                           (Eq. 5) 
From the citrate balance, the total rate of pyruvate oxidation to citrate (J5) is:  
 𝐽5 = 𝐽12𝑓 + 𝐽13 − 𝐽12𝑟                                                                  (Eq. 6) 
The malic enzyme flux (J7) is determined from the model-optimized ratio 
𝐽7
𝐽2𝑐+𝐽7
= 𝑋 and 
the relationship 𝐽2𝑐 + 𝐽7 = 𝐽4 + 𝐽5. Substituting: 
 𝐽7 = 𝑋 ∗ (𝐽4 + 𝐽5)                                                                    (Eq. 7) 
From the pyruvate balance, lower glycolytic flux (J2c) is:  
     𝐽2𝑐 = 𝐽4 + 𝐽5 − 𝐽7                                                              (Eq. 8) 
3-phosphoglycerate flux to serine was assumed to be negligible, so flux from the triose 
phosphates to 3-phosphoglycerate (J2b, middle glycolysis) is:  
𝐽2𝑏 = 𝐽2𝑐                                                                         (Eq. 9) 
Since the stoichiometry of NADH produced per 3-phosphoglycerate produced is 1:1, the 
rate of glycolytic NADH production = J2b. Mitochondrial oxidation of glycolytic NADH 
(J6, via the malate-aspartate shuttle) is thus the residual NADH not used to reduce 
pyruvate to lactate:  
 𝐽6 = 𝐽2𝑏 − 𝐽4                                                              (Eq. 10) 
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The glucose used for both the oxidative and non-oxidative pentose phosphate pathway for 
NADPH and ribose-5-phosphate synthesis is the difference between the measured 
glucose uptake and the rate of glycolytic production of 3-phosphoglycerate (J2b, in 
glucose units):  
 𝐽𝑃𝑃𝑃=𝐽0 − 0.5 ∗ 𝐽2𝑏                                                  (Eq.11) 
The rate of KG oxidation to succinate can be calculated from the KG mass balance:  
  𝐽14 = 𝐽11 + 𝐽12𝑓 − 𝐽12𝑟                                             (Eq.12) 
Succinyl CoA consumption outside the TCA cycle was assumed to be negligible, so: 
𝐽15 = 𝐽14                                                        (Eq.13) 
The rate of malate to OAA can be determined from the malate mass balance:  
 𝐽16 = 𝐽15 − 𝐽7                                                  (Eq.14) 
The citrate-derived oxaloacetate regenerated by fatty acid synthesis from glucose-derived 
pyruvate was assumed to return to the TCA cycle, so that: 
𝐽17 = 𝐽16 + 2 ∗ (𝑔𝑙𝑐 𝑓𝑜𝑟 𝐹𝐴)                                  (Eq.15) 
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RESULTS 
A. Theory on predicting 13C lactate enrichment from 5-13C glutamine to assess TCA 
cycle and malic enzyme activity 
Glutamine supports the growth of many tumors as an anapleurotic and/or 
bioenergetic substrate for the TCA cycle. The proportion of glutamine entering the TCA 
cycle can be followed by 13C tracer analysis in one or more downstream metabolites. For 
this study, we labeled cells with 5-13C glutamine and assessed downstream enrichment in 
lactate exported to the experimental buffer. Enrichment in lactate was chosen as a means 
to quantify fluxes through TCA cycle and malic enzyme reactions. Upon being taken up 
by the cell, glutamine is deaminated to glutamate and then enters the TCA cycle by 
oxidation to -ketoglutarate (KG), where the labeled carbon is retained at position 5 in 
this metabolite (Fig. 2).  Decarboxylation of carbon 1 occurs by KG dehydrogenase, 
resulting in succinyl-CoA that retains the labeled carbon at position 4. Coenzyme A is 
removed by succinate thiokinase, which yields the symmetrical product succinate; since 
succinate dehydrogenase cannot distinguish between carbons 1 and 4, 50% of succinate is 
13C labeled at position 1 and 50% at position 4. The product fumarate is also 
symmetrical, so the labeling pattern is retained as fumarate is converted to the non-
symmetrical product malate. From here there are two different routes that can be taken: 
First, malic enzyme can decarboxylate carbon 4 of malate to generate pyruvate so only 
50% of pyruvate generated in this way is expected to be labeled at carbon 1. Metabolism 
of unlabeled glucose through glycolysis yields unlabeled that is assumed to mix with the 
malic enzyme-derived pyruvate. Some of this pyruvate can be reduced to lactate to give 
the same labeling pattern- single (M1) labeled lactate. Alternatively, some malate carbons 
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are oxidized to oxaloacetate (OAA) such that the labeled carbons are retained in the same 
order. Citrate synthase then catalyzes a condensation reaction with acetyl CoA from 
pyruvate to form citrate, but since carbon 1 of pyruvate is lost upon conversion to 
acetylCoA, citrate is labeled at either carbons 5, or 6,. Reductive carboxylation of 5-13C 
KG to citrate can also yield citrate labeled at carbon 1. As citrate is oxidized to KG the 
label at carbon 6 is removed. Therefore, as the second turn of the cycle begins, KG 
labels occur at position 5 and position 1. However, when KG labeled at carbon 1 is 
oxidized to succinyl-CoA carbon 1 is lost. Therefore, the labeling pattern of succinyl-
CoA after the first turn of the cycle is not expected to change, so double (M2) and triple 
(M3) 13C lactate labeling is not expected to occur.   
The extent of M1 lactate enrichment partly depends on the contribution of glutamate 
dehydrogenase (J11) to generating KG: 
𝐽11
𝐽11+𝐽12𝑓
                                                                        (Ratio 1) 
Lactate M1 enrichment also depends partly on the contribution of malic enzyme (J7) to 
pyruvate production: 
𝐽7
𝐽2𝑏+𝐽7
                                                                         (Ratio 2) 
Therefore, a computational model was developed in which Eqs. 16 and 17 were 
developed as optimized parameters that were varied by the Solver function in Excel to 
reproduce the measured 13C lactate enrichment as close as possible.  
The fraction of glutamine entering the TCA cycle 
 
𝐽11
𝐽10
⁄                                                                   (Ratio 3) 
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was also incorporated in the model because mitochondrial respiration rate imposes a 
constraint on the reducing equivalents NADH and FADH2 generated by the TCA cycle as 
glutamine is oxidized.  
 
Figure 2: 13C distribution in first and second turn of the TCA cycle with [5-13C] glutamine. The labeling 
scheme begins with [5- 13C] glutamine as it enters the TCA cycle upon glutamate (Glu) oxidation (J11). The 
colored circles indicate 13C labeled atoms and the open circles indicate 12C atoms. The carbons are 
numbered starting with position 1 on the left. 13C glutamine enters the cycle labeled at position 5 as 
glutamate is oxidized to -ketoglutarate (KG). As the glutamine carbons travel around the TCA cycle to 
malate (Mal), which is then oxidized by malic enzyme (J7) to pyruvate (Pyr), 13C enrichment in lactate 
(Lac) is expected only at carbon 1. Recycling of 13C as oxaloacetate (OAA) forms citrate (Cit) (J17) is not 
expected to yield additional labeling of succinylCoA (SucC) or malate during subsequent turns of the cycle.  
                                                                                            
 
B. Glucose and glutamine for fatty acid synthesis 
Rapidly dividing tumor cells have high demand for fatty acids to synthesize 
phospholipids for new membranes. Exogenous fatty acids may be limiting, so many 
tumors must use glucose and/or glutamine for de novo synthesis. To assess the proportion 
of glucose and glutamine used to synthesize fatty acids and the overall rate of fatty acid 
synthesis, tumor cells were treated with the fatty acid synthase (FAS) inhibitor C75. 
When FAS is inhibited there should be less demand for glucose and/or glutamine; 
J7 
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therefore, the rate of glucose and/or glutamine uptake from the media should decrease, 
and the extent of the change (the C75-sensitive consumption) should provide an index of 
the rate at which these substrates are used for fatty acid synthesis. Results from these 
experiments were combined with those using 5-13C glutamine as detailed in Section F of 
the Methods section.   
Cells were preincubated in experimental buffer ± 40 µM C75 for 4 h and then 
glucose and glutamine consumption were assessed over three sequential incubation 
periods (1, 2, and 1 h). By 2-way ANOVA (cell line and C75 treatment as main effects), 
there was a borderline significant main effect of C75 treatment on glucose (p=0.0496) 
uptake (Fig. 3), suggesting that glucose may be used to synthesize fatty acids in these cell 
lines. Glucose consumption was most affected in the T47D and MDA231 lines; the rates 
with C75 were 81.6±4.7% (n=4; p=0.02 by one-tailed t-test) and 80.6±2.8% (n=3; p=0.02 
by one-tailed t-test), respectively, of the controls (Fig. 3). In contrast, BoM and LM rates 
were not significantly reduced (glucose consumption with C75 was 97.1±4.8%, n=4, 
p=0.31 and 92.1±5.6%, n=3, p=0.15, of the respective BoM and LM controls). Lactate 
production rate was also measured to determine if the decrease in glucose uptake rate can 
be explained by a reduction in aerobic glycolysis; this could occur if inhibiting fatty acid 
synthesis secondarily reduces ATP consumption, which in turn could affect glycolytic 
rate. Consistent with this possibility, lactate production tended to be lower in the T47D, 
MDA, and LM lines (Fig. 4), although there was no significant main effect of C75 
(p=0.61 by 2-way ANOVA). Reduced aerobic glycolysis accounted for 33.7±13.8%, 
23.9±12.8%, and 78.0±22.4% of C75-sensitive glucose uptake for LM, MDA, and T47D 
lines, respectively. After accounting for the reduction in glucose converted to lactate for 
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these 3 lines, and for the stoichiometry of palmitate synthesis from glucose (see Eq. 4), 
the absolute and normalized rates of glucose diverted to fatty acids did not significantly 
differ (p=0.09, p=0.20, respectively by 1-way ANOVA) between the cell lines (Fig. 6). 
MDA cells notably had a higher glucose consumption rate (Fig. 6A) and a higher 
proportion of glucose diverted to fatty acids (Fig. 6B), but the variability in these 
measurements were too great to yield significant differences. 
Inhibition of FAS had more pronounced effects on glutamine consumption 
(p<0.0001 for main effect of C75 by 2-way ANOVA), suggesting that glutamine is the 
preferred substrate for fatty acid synthesis. Glutamine consumption was significantly 
reduced to similar extents in T47D (68.1±4.4% of controls, n=4, p=0.002), MDA 
(68.4±8.2% of controls, n=3, p=0.026) and BoM (69.7±6.0% of controls, n=4, p=0.014) 
lines, while LM cells were modestly affected (90.8±4.4% of controls, n=3, p=0.087). The 
C75-sensitive glutamine consumption rates did not significantly differ between the lines 
(p=0.12 by 1-way ANOVA; Fig. 7A); however, the lines significantly differed in the 
proportion of glutamine diverted to fatty acids (p=0.01 by 1-way ANOVA). LM cells 
diverted a significantly less (9.2±4.4%) glutamine to fatty acids compared to T47D 
(31.9±4.4%), MDA (31.6±8.2%), and BoM (30.3±6.0%) cells (Fig. 7B). 
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Figure 3 Effect of C75 on glucose uptake: Cells were incubated for 4 hours at 37C with or without 40 M 
C75 and glucose uptake was determined over three sequential 1-2 hr incubations. Glucose concentrations 
were measured by enzymatic assays as described in the methods. Data are mean   standard error of three 
(LM, MDA231) or four (BoM, T47D) independent experiments. Asterisks * denote p< 0.05 compared to 
corresponding control by t-test.  
 
 
Figure 4 Effect of C75 on lactate production: Cells were incubated for 4 hours at 37C with or without 40 
M C75. Lactate concentrations were measured by enzymatic assays as described in the methods. Data are 
mean   standard error of three (LM, MDA231) or four (BoM, T47D) independent experiments. Asterisks * 
denote p< 0.05 compared to corresponding control by t-test.  
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Figure 5 Effects of C75 on glutamine consumption: Cells were incubated for 4 hours at 37C with or 
without 40 M C75. Glutamine concentrations were measured by enzymatic assays as described in the 
methods. Data are mean   standard error of three (LM, MDA231) or four (BoM, T47D) independent 
experiments. Asterisks * denote p< 0.05 compared to corresponding control by t-test. 
 
 
Figure 6 Absolute and fractional rates of C75-sensitive glucose diverted to fatty acids: (A) The absolute 
rates of C75-senstive glucose to fatty acid were determined after subtracting the rate of C75-sensitive 
glucose converted to lactate. One-way ANOVA indicated no significant cell line effect (p=0.09) (B) The 
absolute rates in (A) were normalized to the rates of glucose uptake for the controls. One-way ANOVA 
indicated no significant cell line effect (p=0.20). 
(A) 
(B) 
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Figure 7 Absolute and fractional rates of C75-sensitive glutamine diverted to fatty acids: (A) The absolute 
rates of C75-senstive glutamine to fatty acid were calculated as the difference in control and C75 rates. 
One-way ANOVA indicated no significant cell line effect (p=0.12). (B) The absolute rates in (A) were 
normalized to the rates of glutamine uptake for the controls. One-way ANOVA indicated a significant cell 
line effect (p=0.01). Means sharing the same letter are not significantly different. 
 
C. 13C lactate enrichment 
Cells were pre-equilibrated for 20-22 h in cell culture media with 1.5 mM 5-13C 
glutamine and then another 5 h in experimental buffer with 5mM glucose and 1.5 mM 5-
13C glutamine to allow isotopic steady-state labeling of intracellular metabolites; control 
cells run in parallel were incubated with 5 mM glucose and no glutamine to assess 
background 13C labeling. Compared to controls, all cell lines given 13C-glutamine had 
significantly less unlabeled (M) lactate and significantly more 13C lactate (Fig. 8A, 8B). 
(A) 
(B) 
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Importantly, virtually all 13C enrichment occurred as the M1 isotopologue (i.e., lactate 
with a single 13C atom) with virtually none detected as M2 or M3 (Table 2). These results 
are consistent with the predicted M1-only isotopologue labeling (Fig. 2) that is the basis 
for the computational model to infer many of the fluxes within our metabolic map (Fig. 
1). Furthermore, 13C enrichment in lactate in all four cell lines is consistent with use of 
glutamine as an anaplerotic substrate to replace TCA cycle malate oxidized by malic 
enzyme to produce NADPH (Fig. 1). It should also be noted that the fraction of M1 
lactate did not increase for any cell line from the first to the second incubation period, 
suggesting that isotopic steady-state labeling was reached.  
 
 
Figure 8 M and M1 lactate content. Cell lines were equilibrated 26-27 h without or with 5-13C glutamine. 
Fractional 13C lactate content was determined by mass spectrometry. (A) Unlabeled (M) lactate content. 
(B) Single 13C labeled (M1) lactate content. Data are mean ± standard error of 4 experiments. Asterisks * 
denote p< 0.05 compared to corresponding control cells this analysis was done by t-test.  
(A) 
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The specific 13C labeling enrichment was determined by subtracting background 
enrichment (Table 2). LM cells M1 lactate content was 2 to 5-fold greater than the other 
three lines; T47D cells exhibited intermediate M1 enrichment approximately 2 to 3-fold 
higher than BoM and MDA cells. A computational model was used to optimize Ratios 1, 
2, and 3 to reproduce as closely as possible the measured labeling. For this, the rates of 
glucose consumption (J0), lactate production (J4), mitochondrial respiration (JRR), and 
glutamine consumption (J10) (see A. Skubiz Honor’s thesis for details), together with 
fractional glucose and glutamine used for fatty acid synthesis, were model inputs that set 
the constraints for optimizing Ratios 1-3. The model closely reproduced lactate labeling 
seen for T47D, BoM and MDA cells, but was less effective for the LM line (Table 2). 
The limitation for the LM line was based on the low measured mitochondrial respiration 
rate coupled with the high measured M1 lactate enrichment. The respiration rate set a low 
limit for Ratio 2, and correspondingly this also limited Ratio 3. Nevertheless, the model 
is a reasonably good fit to these cell lines for estimating glucose and glutamine 
metabolism.  
The model-optimized Ratios are shown in Table 3. The contribution of malic 
enzyme to pyruvate production differed significantly between cell lines (p<0.0001) and 
was highest for T47D and LM lines; this was expected given that these lines had the 
highest enrichment of M1 lactate. The contribution of glutamate oxidation (J11) to KG 
production differed significantly (p<0.0001); both MDA-derived metastatic variants 
generated the majority of KG from glutamate (98% for LM and 65% for BoM), 
suggesting low isocitrate dehydrogenase activity in these cells. The fraction of glutamine 
 
 
  24 
converted to KG also differed significantly between the lines (p=0.001); the less 
aggressive T47D line shunted the highest fraction to KG (65%), suggesting the more 
aggressive LM, MDA, and BoM lines (which shunted 35, 43, and 54%, respectively of 
glutamine to the TCA cycle) used a higher proportion of glutamine for protein or small 
peptide (e.g., glutathione) synthesis. 
 
Table 2. Measured and Modeled 13Carbon Lactate Enrichment  
Measured 13C Labeling            Predicted 13C Labeling 
 
M M1 M2 M3 M M1 M2 M3 Model error 
LM 0.9819±
0.0006c 
0.0178±0.000
6c 
0.0003±0 <0.0001±0 0.9864±0.0018 0.0136±0.00
18 
0 0 0.0092±0.0031 
BoM 0.9954±
0.0002b 
0.0046±0.000
2b 
<0.0001±0 <0.0001±0 0.9954±0.0002 0.0046±0.00
02 
0 0 0.0002±0.0001 
MD
A 
0.0066±
0.0006b 
0.0033±0.000
6b 
<0.0001±0.00
01 
<0.0001±0 0.9966±0.0006 0.0034±0.00
06 
0 0 0.0006±0.0001 
T47
D 
0.9913±
0.0009a 
0.0083±0.000
6a 
0.0003±0.000
1 
0.0002±0.0002 0.9916±0.0007 0.0084±0.00
07 
0 0 0.0011±0.0004 
Unlabeled (M), single- (M1), double- (M2), and triple- (M3) 13C labeled lactate produced by cell lines 
metabolizing 5-13C glutamine was measured by mass spectrometry. Computational modeling was used to 
reproduce the labeling pattern within the constraints of the measured fluxes J0, J4, J11, and JRR (see Fig. 1). 
Data are the mean  the standard error of four experiments per cell line. This table compares the measured 
enrichment with the predicted enrichment from the computational model for 13C labeling. The model error 
is the sum of the absolute value of the difference between M-M3 predicted and measured. Means that share 
common letters within a column are not significantly different (significance level p<0.05).  
 
 
 Table 3. Model-optimized flux ratios  
 LM BoM MDA T47D 
𝐽7
(𝐽2𝑏 + 𝐽7)
⁄  0.0278±0.0040a 0.0132±0.0008b 0.0127±0.0021b 0.0370±0.0028a 
𝐽11
(𝐽11 + 𝐽12𝑓)
⁄  0.9821±0.0131d 0.6496±0.0302c 0.4988±0.0044b 0.4337±0.0092a 
𝐽11
𝐽10
⁄  0.3559±0.0504c 0.5381±0.0093a,b 0.4350±0.0158b,c 0.6518±0.0387a 
     
Table 3 Optimized flux ratios from the computational model. Data are means   the standard error of four 
experiments. The means that share common letters within a row are not significantly different (significance 
level p<0.05).  
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D. Pathway Fluxes 
From the model-optimized flux ratios and the measured fluxes (highlighted in red, 
Table 4), the remaining fluxes for each cell line were determined as detailed in Section F 
of the methods. Inferred fluxes will be highlighted here, as differences in the measured 
fluxes have previously been detailed (see A. Skubiz thesis). 
Measurement of lactate production alone does not necessarily report aerobic 
glycolysis if there are glycolysis-independent sources of pyruvate (e.g., malic enzyme). 
Since malic enzyme’s contribution to pyruvate (and by extension, lactate) differed 
significantly between the cell lines (Table 3), removal of this contribution could impact 
potential differences in aerobic glycolysis. However, in this case aerobic glycolysis 
remained not significantly different between the three metastatic lines (MDA, LM, and 
BoM rates: 31.3±2.1, 30.9±1.0, and 28.2±0.5 nmol lactate/min x mg) but significantly 
higher than T47D cells (9.47±0.43 nmol lactate/min x mg). Lactate production alone does 
not assess total glycolysis (glucose to pyruvate) since some glycolytic-derived pyruvate is 
used for other purposes (e.g., mitochondria oxidation; fatty acid synthesis). Total 
glycolysis (J2c and J2b) was determined from measurements of mitochondrial respiration 
rate, lactate production rate, C75-sensitive glucose and glutamine consumption, and 
glutamine used to support malic enzyme flux. While aerobic glycolysis did not differ 
between MDA, BoM, and LM cells, total glycolytic flux of MDA cells was significantly 
greater than BoM cells (p=0.02), while LM flux did not differ from either of these lines. 
The MDA-BoM difference was a consequence of a significantly higher rate of 
mitochondrial pyruvate uptake (J5) by MDA cells. Notably, mitochondrial pyruvate 
uptake for LM and BoM cells was not different, but substantially diverged from their 
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parent MDA231 cells (Table 4). This trend was also apparent with mitochondrial uptake 
and oxidation of glycolytic-derived NADH (J6), and with TCA cycle reaction fluxes (J12f, 
J14, J15, J16, and J17). These results further suggest significant changes in mitochondrial 
function between the MDA231 lines and the BoM and LM lines. It is also worth 
mentioning that the LM TCA cycle did not operate as a continuous cycle as with the 
other cell lines in that virtually all pyruvate entering was shunted to fatty acid synthesis, 
so the forward cycle was interrupted from citrate to KG. However, from KG to malate 
the forward cycle was supported by glutamine influx but was again interrupted with 
virtually no malate being oxidized to oxaloacetate (Table 4); oxaloacetate for citrate 
synthesis was effectively ‘recycled’ from that released from citrate used during fatty acid 
synthesis. 
Glucose uptake that was not used for aerobic glycolysis, mitochondrial oxidation, 
or fatty acid synthesis was assumed to be shunted into the oxidative and non-oxidative 
pentose phosphate pathways. These experiments did not allow differentiation between 
these two pathways and so were grouped together as a single pentose phosphate pathway 
(PPP) flux (Table 4). The MDA and LM PPP fluxes were not different, but both 
exhibited significantly, or borderline significantly (for LM vs. T47D, p=0.0502) greater 
fluxes compared to T47D cells. Glucose used by the PPP in the BoM line was no 
different from the T47D cells, which was unexpected given that demand for de novo 
nucleotide synthesis is predicted to be higher in the more rapidly proliferating BoM line. 
When normalized to total glucose uptake rate, BoM glucose shunted to the PPP remained 
significantly lower than the other three cell lines, which were not different from one 
another (percent glucose used by PPP for T47D, MDA, LM, and BoM lines was 
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31.2±3.7%, 23.5±3.0%, 22.5±2.3%, and 12.5±3.1%, respectively); it was surprising that 
the least metastatic, slow growing T47D line tended toward using the highest proportion 
of glucose for the PPP. 
Finally, malic enzyme activity was approximately two-fold higher in LM cells 
compared to the other three lines (Table 4). Malic enzyme account for approximately 
98% of malate consumption in these cells; by comparison, malic enzyme consumed 
approximately 21%, 45%, 28% of malate in MDA, BoM, and T47D cells, respectively. 
 
Table 4. Measured and Modeled Fluxes 
   T47D MDA231 BoM LM 
J0 (nmol glc/min x mg) 7.79±0.26a 23.1±1.0b 16.6±0.53c 20.5±0.1d 
J1+J3 (nmol HxP/min x 
mg) 2.43±0.33a,b 5.44±0.63c 2.07±0.59a 4.59±0.46b,c 
J2a nd nd nd nd 
J2b (nmol TrP/min x mg) 10.7±0.5a 35.4±2.2b 29.1±0.4c 31.7±1.1 b,c 
J2c (nmol 3PG/min x mg) 10.7±0.5a 35.4±2.2b 29.1±0.4c 31.7±1.0b,c 
J4 (nmol lac/min x mg) 9.83±0.43a 31.7±2.0b 28.6±0.5b 31.8±1.1b 
J5 (nmol pyr/min x mg) 1.28±0.03a 4.15±0.13b 0.83±0.07c 0.80±0.02c 
J6 (nmol NADH/min x 
mg) 0.87±0.03a 3.69±0.16b 0.44±0.05c 0.05±0.05d 
J7 (nmol mal/min x mg) 0.41±0.03a 0.46±0.04a 0.39±0.02a 0.91±0.15b 
J8 nd nd nd nd 
J9 nd nd nd nd 
J10 (nmol gln/min x mg) 1.24±0.12a 3.82±0.18b 1.66±0.06a 3.44±0.27b 
J11 (nmol glu/min x mg) 0.81±0.05a 1.66±0.04b 0.89±0.03a,c 1.22±0.14c 
J12f (nmol cit/min x mg) 1.05±0.03a 1.67±0.04b 0.48±0.07c 0.02±0.02d 
J12r (nmol aKG/min x 
mg) 0.39±0.04a,c 1.21±0.06b 0.50±0.02a 0.32±0.03c 
J13 (nmol cit/min x mg) 0.62±0.04a 3.68±0.15b 0.85±0.03a,c 1.09±0.02c 
J14 (nmol aKG/min x 
mg) 1.46±0.05a 2.13±0.05b 0.87±0.09c 0.93±0.17c 
J15 (nmol suc/min x mg) 1.46±0.05a 2.13±0.05b 0.87±0.09c 0.93±0.17c 
J16 (nmol mal/min x mg) 1.05±0.03a 1.67±0.04b 0.48±0.07c 0.02±0.02d 
J17 (nmol oaa/min x mg) 1.28±0.03a 4.15±0.13b 0.83±0.07c 0.80±0.02c 
     
All fluxes are expressed as nmol of substrate consumed per minute per mg cell protein. Data are mean   
standard error of 4) experiments for each cell line. The red boxes are the measured fluxes. The remaining 
fluxes were inferred from the computational model optimizing three flux ratios to reproduce the measured 
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13C enrichment in lactate. Glucose used for the oxidative and non-oxidative pentose phosphate pathways 
(J1 and J3, respectively could not be resolved and so were combined to report overall pentose phosphate 
flux. Means sharing common superscripts do not significantly differ the significance level P<0.05. nd: not 
determined. Abbreviations: glc: glucose; HxP: hexose phosphates, including glucose-6-phosphate and 
fructose-6-phosphate; TrP: triose phosphates, including glyceraldehyde-3-phosphate and 
dihydroxyacetone phosphate; 3PG: 3-phosphoglycerate; lac: lactate; pyr: pyruvate; mal: malate; gln: 
glutamine; glu: glutamate; cit: citrate; aKG: -ketoglutarate; suc: succinyl-CoA; oaa: oxaloacetate.  
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DISCUSSION 
The overall goal of this study was to determine if metastatic sub-clones that 
preferentially invade and grow in lung or bone tissue exhibit metabolic differences from 
the parent MDA231 breast cancer line. Such metabolic plasticity may be important for 
tumor growth in different tissue microenvironments, and may guide development of 
tumor-specific, metabolic-targeted therapies. The major glucose-consuming pathways 
were quantified with a moderate degree of resolution using the principles of 13C 
metabolic flux analysis with 5-13C glutamine and unlabeled glucose as substrates. The 
major finding from this study is that LM and BoM cells exhibit significant metabolic 
differences from each other and from the MDA231 parent line. Specifically, 
mitochondrial oxidation of both pyruvate and glutamine is lower in both the LM and 
BoM lines; consistent with this, less glycolytic NADH is shuttled into mitochondria for 
oxidation and a greater fraction of glucose is converted to lactate in the BoM and LM 
lines. Other notable differences include lower PPP flux in BoM cells, lower de novo fatty 
acid synthesis flux in both BoM and LM cells, and higher malic enzyme flux in LM cells.  
 Glucose and glutamine are critical nutrients for cancer cell growth. Both of these 
nutrients can be metabolized to substrates that are oxidized in the TCA cycle to produce 
ATP. Glucose is transformed to pyruvate through glycolysis which then enters the TCA 
cycle or is reduced to lactate (4). Pyruvate entering the TCA may be incompletely 
oxidized and instead used for fatty acid synthesis as acetylCoA derived from the TCA 
cycle metabolite citrate. In addition to pyruvate, glycolysis generates other metabolites 
that are substrates for anabolic pathways. Glucose-6-phosphate is oxidized through the 
oxidative pentose phosphate pathway to produce ribose phosphates for synthesis of 
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nucleic acids (2) and NADPH for a number of biosynthetic pathways and for protection 
against reactive oxygen species (ROS). Fructose-6-phosphate and glyceraldehyde-3-
phosphate are substrates for the non-oxidative pentose phosphate pathway (running in 
reverse) that also produces ribose phosphates. Serine and glycine are synthesized from 3-
phosphoglycerate; serine can be further metabolized in the folate cycle to support 
nucleotide synthesis. The majority of glutamine not used for protein synthesis is 
deaminated within mitochondria to glutamate by glutaminase (GLS). Glutamate is 
oxidized by glutamate dehydrogenase to the TCA cycle metabolite KG. The 
deamination of glutamine to glutamate generates nitrogen (as ammonia) which is used for 
nucleotide biosynthesis and nonessential amino acids (1). Production of KG from 
glutamine is important to replace TCA cycle metabolites removed from the cycle by 
other reactions. For example, malic enzyme oxidizes malate to pyruvate which can either 
re-enter the TCA cycle or be reduced to lactate. When malate is oxidized in this way, 
NADPH is produced which contributes to maintaining the cellular redox state for 
biosynthetic reactions and protection against ROS. (1). Glutamate is also a substrate for 
glutathione synthesis; this tripeptide is important for protection against ROS as well as 
for biosynthetic reactions. Cancer cells have a higher flux of substrates through many 
anabolic pathways to produce nucleotides, fatty acids and non-essential amino acids 
necessary for their rapid proliferation. In this way, glucose and glutamine consumption 
rates are higher in cancer cells. However, different types of cancer cells may exhibit 
differences in fluxes through specific pathways as a result of differences in either their 
capacity to transport exogenous nutrients from the extracellular fluid (ECF), their 
expression of genes coding for different pathways, or the composition of the 
 
 
  31 
ECF/availability of nutrients given the tissue in which the cells proliferate. From this 
perspective, metastatic cancers that preferentially grow in different organs may do so 
partly because of metabolic differences. 
 As expected, the aggressive metastatic MDA231 cell line exhibited significantly 
greater total glycolytic (glucose to pyruvate) and aerobic glycolytic (glucose to lactate) 
flux compared to the less metastatic T47D cell line (Fig 9). The importance of increased 
aerobic glycolysis is likely for generating glycolytic intermediates at a rate sufficient to 
support anabolic processes (5), but may also be important for adequate supply of ATP. 
These results are similar to another study showing 2-3 fold higher glucose consumption 
and lactate production for MDA-MBA-231 cells (6). The high aerobic glycolysis of more 
metastatic cells is often associated with lower mitochondrial activity; this has often been 
interpreted that metastatic cells have dysfunctional mitochondria deficient in pyruvate 
oxidation and ATP synthesis. Surprisingly, we found that MDA231 cells had 
significantly higher respiration rate and TCA cycle fluxes compared to T47D cells. 
Pyruvate flux to citrate to meet greater demand for fatty acid synthesis was a notable 
contributor to the cycle. While the proportion of oxygen used to synthesize ATP was not 
assessed, greater TCA cycle activity implies that MDA mitochondria are functional and 
important contributors to cellular ATP synthesis. The higher rates of aerobic glycolysis 
and mitochondrial respiration and TCA cycle activity imply that MDA cells have a 
significantly greater ATP demand. While some of this may be due to greater activity of 
ATP-dependent anabolic pathways, the differences in cell morphology may also 
contribute. MDA231 cells are more elongated, with many having neurite-like extensions; 
they also do not adhere together, while T47D cells are more rounded and form tight 
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clusters. These observations suggest MDA231 cells have a greater plasma membrane 
surface area:cell volume ratio that would promote greater plasma membrane ion cycling 
and correspondingly a greater demand for ATP to maintain appropriate ion gradients. 
Further experiments are required to assess how differences in cell morphology might 
contribute to ATP demand and whether the efficiency of mitochondrial ATP synthesis 
differs. 
 Oxidative/non-oxidative PPP flux was 2.2-fold greater in MDA cells; these cells 
thus have higher NADPH and pentose phosphate demand for redox homeostasis and 
nucleotide synthesis than T47D cells (2). Experiments are in progress to resolve the 
proportion of glucose through the oxidative and non-oxidative pathways It was somewhat 
surprising that the proportion of total glucose used by the PPP tended to be higher for 
T47D than MDA cells, (31.2±3.7% vs. 23.5±3.0% of total glucose, respectively; p=0.36) 
given the more malignant nature of the latter cell line. Some of this difference could be 
attributed to MDA cells tending to use a greater proportion of glucose for fatty acid 
synthesis (5.1±1.5% vs. 1.4±1.1%, respectively; p=0.32). Since oxidative PPP flux is 
subject to strong feedback inhibition by NADPH, MDA231 cells may have less demand 
for this cofactor. This would most likely derive from less consumption for antioxidant 
defenses given the greater demand for fatty acid synthesis and potentially other 
biosynthetic reactions. Glutathione and thioredoxin reductases are major NADPH 
consumers to protect against ROS; MDA cells could either produce less ROS and so 
require less NADPH, or have deficits in reductase activities.  
 Glutamine consumption was 3-fold higher in the MDA cells. One reason for this 
was to support the significantly higher rate of fatty acid synthesis by reductive 
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carboxylation of KG. The flux of both glucose and glutamine to fatty acid is sufficiently 
high to indicate MDA cells could be vulnerable by therapeutically targeting this pathway. 
However, a significantly greater proportion of glutamine used by T47D cells entered the 
TCA cycle (Table 3). This suggests MDA cells preferentially use glutamine for processes 
other than resupplying TCA cycle metabolites removed by anabolic reactions; such 
processes would include glutamine/glutamate use for protein and glutathione synthesis. 
Higher MDA demand for protein synthesis is expected based on the greater proliferation 
rate of this cell line. Interestingly, de novo glutathione synthesis is predicted to be 
relatively high if MDA cells are deficient in glutathione reductase. Experiments are 
ongoing to assess the proportion of glutamine used for glutathione synthesis.  
 
 
Figure 9: Comparison of MDA231 to T47D fluxes. Numbers are the ratios of MDA to T47D fluxes (Table 
3) for each group of reactions. Green and red arrows denote MDA fluxes significantly greater than or less 
than, respectively, the corresponding T47D fluxes. Blue arrows denote fluxes that were not significantly 
different. 
 
The malignant LM and BoM subclones exhibit significant metabolic differences 
from their parent MDA231 line, which supports our hypothesis and is consistent with 
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such changes contributing to organ-specific growth of these lines. The most notable 
difference is that both lines have significantly lower mitochondrial TCA cycle and 
respiratory chain activities (Figs 10 and 11).  
 
Figure 10:  Comparison of LM to MDA231 fluxes. Numbers are the ratios of LM to MDA231 fluxes (Table 
3) for each group of reactions. Green and red arrows denote MDA fluxes significantly greater than or less 
than, respectively, the corresponding T47D fluxes. Blue arrows denote fluxes that were not significantly 
different. 
 
Such changes may be particularly important for LM cells that preferentially metastasize 
to the lungs, which is a unique organ in two ways- they receive 100% of cardiac output 
and thus have the highest blood flow per mass tissue of any organ (Table 5) and have the 
highest dissolved oxygen content (PO2 approximately 100 mmHg vs. systemic organs 
where PO2 is approximately 20 mmHg) due to their close proximity to atmospheric air. 
Mitochondria are primary producers of ROS through electron leak to oxygen from the 
respiratory chain to produce superoxide. The rate of superoxide production partly 
depends on the concentration of dissolved oxygen; cells in the lungs are thus more 
susceptible to ROS production, and hence to oxidative stress. However, ROS production 
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also depends on the redox state of the respiratory chain carriers and the TCA cycle 
dehydrogenase prosthetic groups (e.g., flavin, thiamine pyrophosphate, and iron-sulfur 
groups); the greater proportion of reduced prosthetic groups, the more likely electron leak 
to oxygen would occur. These groups can be maintained in a more oxidized state if 
substrate supply to mitochondria is restricted.  
 
Figure 11:  Comparison of BoM to MDA231 fluxes. Numbers are the ratios of BoM to MDA231 fluxes 
(Table 3) for each group of reactions. Green and red arrows denote MDA fluxes significantly greater than 
or less than, respectively, the corresponding T47D fluxes. Blue arrows denote fluxes that were not 
significantly different. 
 
Consistent with this possibility, LM cells oxidize pyruvate at only 20% the rate of MDA 
cells; further, isocitrate dehydrogenase activity is virtually absent, which would not only 
eliminate ROS production by this enzyme, but also by KG dehydrogenase due to further 
limiting supply of this substrate. In another experiment, proteomic comparison of MDA-
MB-438 cells and a sub-clone that metastasizes to lung, it was found that peroxiredoxin 
overexpression was important for lung metastasis (13).  Peroxiredoxin (PRDX2) protects 
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against oxidative stress by reducing hydrogen peroxide to water (13). By comparison, 
PRDX2 expression in bone tissue was decreased (13); this is consistent with growth in 
the lungs requiring adjustments that limit ROS levels. LM cells also shunt the lowest 
proportion of glutamine to KG (Table 3); this may also contribute to restricting TCA 
cycle substrate availability in addition to making more glutamate available for 
glutathione synthesis. The blunted fatty acid synthesis is likely a secondary consequence 
of limiting TCA cycle substrate availability; presumably LM cells would have to 
compensate for this by enhanced reliance on exogenous fatty acids. Increased availability 
of NADPH by significantly enhanced malic enzyme flux would also reduce oxidative 
stress. Taken together, these findings are consistent with metabolic adjustments in LM 
cells to minimize ROS production and oxidative stress in the high oxygen environment of 
the lungs.  
In contrast to the lungs, bone tissue has the lowest blood flow (Table 5). Since 
blood flow determines the rate at which oxygen, glucose, and glutamine are delivered, 
BoM metabolism may reflect adaptation to this nutrient-limited environment. These cells 
use a significantly smaller proportion of glucose for the PPP (12.2±3.1%) than the other 
three lines and have the lowest PPP flux; this is consistent with lower demand for 
NADPH, possibly due to limited oxygen availability and hence less ROS production. 
However, these cells proliferate at a rate greater than MDA cells and close to that of LM 
cells in vitro so it is difficult to understand how the low PPP flux could provide pentose 
phosphates at a rate adequate to meet the demand for nucleotide synthesis. Low 
mitochondrial respiratory chain and TCA cycle activities could reflect the limited oxygen 
supply to bone. They also consume significantly less glutamine than the MDA and LM 
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lines, which could be a consequence of limited mitochondrial substrate oxidation 
capacity. The finding that BoM cells have the highest lactate:glucose ratio further 
suggests they rely more heavily on glycolytic ATP production for their energy. In this 
respect, BoM cells may be particularly susceptible to therapies that interfere with 
glycolysis. 
 
Table 5. Mass adjusted comparison of tissue blood flow rates. 
Tissue Blood flow (ml/min x 100 g 
tissue) 
Reference 
Bone 1.5-2.0 Heinonen et al 2013 
Dermis (skin) 4-10 Textbook Physiol.  
Skeletal muscle 5-10 Textbook Physiol. 
Intestine 30 Textbook Physiol. 
Brain 57 Textbook Physiol. 
Heart 70 Textbook Physiol. 
Kidney 350 Textbook Physiol. 
Lung 300-500 calculated 
 
  
 
 
  38 
CONCLUSIONS 
 
In conclusion, LM and BoM cells exhibit significant metabolic differences from each 
other and from the MDA231 parent line. This supports our hypothesis of metabolic 
reprogramming for organ specific growth. TCA cycle and mitochondrial respiratory 
chain activities are lower for the LM and BoM lines, while both convert a greater fraction 
of glucose to lactate. Malic enzyme flux was twice as great in LM cells. It appears that 
LM metabolism has adjusted to minimize ROS levels in the high oxygen content of the 
lungs by limiting substrate availability to mitochondria while enhancing malic enzyme 
production of NADPH. These cells may be vulnerable to inhibition of antioxidant 
defense mechanisms and/or glycolysis. The BoM cells shunted the smallest fraction of 
glucose through the PPP and the largest fraction to lactate, which could be an adaptation 
to the low oxygen availability in bone because of the low blood flow to this tissue. These 
results suggest that LM cells may be vulnerable to inhibition of antioxidant defense 
enzymes while BoM cells may be more vulnerable to glycolytic inhibition. MDA231 
cells were unique in having both high glycolytic and mitochondrial activities, as well as 
3-5-fold higher de novo fatty acid synthesis. These cells may be vulnerable to targeted 
inhibition of fatty acid synthesis. Taken together, these metabolic differences highlight 
pathways that could help treat tissue-specific metastatic breast cancers.  
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